What is Think Bioscience?
Think Bioscience is a privately held small molecule drug discovery company headquartered in Boulder, Colorado. The company distinguishes itself by targeting complex biological mechanisms that have eluded traditional drug development. Its multidisciplinary team leverages expertise across synthetic biology, protein biophysics, applied enzymology, computational chemistry, and medicinal chemistry. This integrated approach enables the creation of novel therapeutic programs aimed at addressing severe diseases where current treatment options are limited.
How much funding has Think Bioscience raised?
Think Bioscience has raised a total of $73.9M across 3 funding rounds:
Angel/Pre-Seed
$1.9M
Seed
$17M
Series A
$55M
Angel/Pre-Seed (2021): $1.9M, investors not publicly disclosed
Seed (2022): $17M led by Xora Innovation, Innovation Endeavors, and AV8 Ventures
Series A (2026): $55M supported by Janus Henderson Investors, Regeneron Ventures, Crescent Enterprises, AV8 Ventures, MBX Capital, Colorado Venture Partners, and Innovation Endeavors
Key Investors in Think Bioscience
Janus Henderson Investors
Janus Henderson Investors is a global investment management firm providing a broad range of investment solutions and advisory services. They focus on helping clients achieve financial objectives through disciplined investment strategies and in-depth research.
Regeneron Ventures
Regeneron Ventures invests in innovative biotechnology and pharmaceutical companies, aiming to support the development of groundbreaking therapies and technologies in the healthcare sector.
Crescent Enterprises
Crescent Enterprises, Inc. is an oil and gas services company specializing in advanced technologies and equipment for the hydrocarbon value chain, from exploration to refining.
What's next for Think Bioscience?
The substantial enterprise-level funding and recent strategic investment position Think Bioscience for accelerated development and potential market entry. This capital infusion is expected to fuel the advancement of its pipeline, enhance its research and development capabilities, and potentially expand its team of scientific experts. The company's focus on 'undruggable' targets suggests a long-term vision for tackling challenging diseases, and this financing provides the necessary runway to pursue these ambitious goals. Future strategic partnerships or further funding rounds may be anticipated as the company progresses through clinical development stages.
See full Think Bioscience company page
